Collaborative Wilms Tumour Africa Project
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01991652|
Recruitment Status : Recruiting
First Posted : November 25, 2013
Last Update Posted : November 15, 2016
Significant progress has been made in the treatment of Wilms tumor in high income countries, where survival is now around 85% - 90%. Survival in low income countries is much lower; specific challenges include late presentation, malnutrition, less intense supportive care facilities and failure to complete treatment.
A comprehensive treatment guideline was introduced in Malawi in 2006 which included nutritional support and social support to enable parents to complete treatment. Survival has increased to around 50%; 95% of children completed their treatment. A multi-disciplinary group of African clinicians and 'state of the art' experts produced a consensus treatment guideline for children with Wilms tumor in sub-Saharan Africa. This guideline will be implemented as a multi-center prospective clinical trial in 2014 in six - eight institutes, expecting about 200 new patients per year.
The hypothesis is that 2 year event free survival will be 50%, with <10% failure to complete treatment and <10% treatment related mortality. Other research questions include efficacy and toxicity of preoperative chemotherapy and the comparison of surgical staging, local pathology and central review pathology in stratifying postoperative chemotherapy.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||Collaborative Wilms Tumour Africa Project|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2019|
Children diagnosed with a Wilms tumour receive SIOP PODC Wilms tumour treatment; preoperative chemotherapy, surgery and postoperative chemotherapy (= standard care).
One group of patients.
- Event free survival [ Time Frame: 2 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01991652
|Contact: Trijn Israels, MD PhDfirstname.lastname@example.org|
|Contact: Elizabeth Molyneux, Profemail@example.com|
|Mbingo Mission Hospital||Recruiting|
|North West Cameroon, Cameroon|
|Contact: Peter Hesseling firstname.lastname@example.org|
|Principal Investigator: Francine Kouya, MD|
|Tikur Anbessa Specialized Hospital||Recruiting|
|Addis Abeba, Ethiopia|
|Contact: Haileyesus David, MD email@example.com|
|Principal Investigator: Yasar Celiker, MD|
|Korle Bu Hospital||Recruiting|
|Contact: Lorna Renner, MD firstname.lastname@example.org|
|Principal Investigator: Lorna Renner, MD|
|College of Medicine||Recruiting|
|Contact: Elizabeth Molyneux, Prof email@example.com|
|Contact: Neil Kennedy, Prof firstname.lastname@example.org|
|Principal Investigator: Elizabeth Molyneux, Prof|
|Study Chair:||Trijn Israels, MD PhD||VU University Medical Center|